oral, once a day tablet that was developed for patients 12 years and over to help prevent severe anemia from SCD that can lead to permanent damage to the brain and other organs.
By increasing hemoglobin’s affinity to oxygen, it halts polymerization (the root cause of SCD) which is the clumping and sticking together into rigid long rods that deform blood cells.
Researchers say Oxbryta can reduce patients’ risk of stroke as well as the need for blood transfusions. Most common side effects are headache, diarrhea, nausea, rash, fever and tiredness.
NEXT, THE NOT SO GREAT NEWS.
Adakveo and Oxbryta could both be revolutionary treatments for Sickle Cell Disease but each costs approximately about $100,000 per year and must be taken for life!
The cost for Oxbryta oral tablet 500 mg is around $10,885 for a supply of 90 tablets. Oxbryta is available as a brand name drug only, a generic version is not yet available. Adakveo costs between $7,000 and $9,500 a month.
The management of sickle-cell disease is already expensive because of health complications and repeated hospitalizations. It now costs an average of about $10,000 a year to treat children, and roughly $30,000 a year to treat adults for complications like pain crises, organ damage and strokes.
Unfortunately, for many, the devastatingly expensive annual cost of these drugs only proves the claims about the average person not having fair access to cutting edge medicines.
CHECK WITH YOUR DOCTOR TO DISCUSS OBTAINING THESE NEW SICKLE CELL DISEASE INNOVATIONS.
After discussing these innovative new medications with your doctor or specialist, you may find the hope you’ve been looking for in managing your Sickle Cell.
Don’t let the huge price tags frighten you! Check with your insurance provider and remember that patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide